N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients

Shih Ping Hsu, Chih Kang Chiang, Shao Yu Yang, Chiang-Ting Chien

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background/Aims: To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients. Methods: Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed. Results: During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia. Conclusions: Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.

Original languageEnglish
JournalNephron - Clinical Practice
Volume116
Issue number3
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Acetylcysteine
Renal Dialysis
Anemia
Oxidative Stress
8-epi-prostaglandin F2alpha
Erythropoietin
Hematocrit
Case-Control Studies
Outpatients
Demography

Keywords

  • Anemia
  • Hemodialysis
  • N-Acetylcysteine
  • Oxidative stress
  • Oxidized low-density lipoprotein

ASJC Scopus subject areas

  • Nephrology

Cite this

N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. / Hsu, Shih Ping; Chiang, Chih Kang; Yang, Shao Yu; Chien, Chiang-Ting.

In: Nephron - Clinical Practice, Vol. 116, No. 3, 01.10.2010.

Research output: Contribution to journalArticle

@article{088a13edae14449ebc211ae98c3e3a42,
title = "N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients",
abstract = "Background/Aims: To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients. Methods: Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed. Results: During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia. Conclusions: Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.",
keywords = "Anemia, Hemodialysis, N-Acetylcysteine, Oxidative stress, Oxidized low-density lipoprotein",
author = "Hsu, {Shih Ping} and Chiang, {Chih Kang} and Yang, {Shao Yu} and Chiang-Ting Chien",
year = "2010",
month = "10",
day = "1",
doi = "10.1159/000317201",
language = "English",
volume = "116",
journal = "Nephron - Clinical Practice",
issn = "1660-2110",
number = "3",

}

TY - JOUR

T1 - N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients

AU - Hsu, Shih Ping

AU - Chiang, Chih Kang

AU - Yang, Shao Yu

AU - Chien, Chiang-Ting

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background/Aims: To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients. Methods: Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed. Results: During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia. Conclusions: Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.

AB - Background/Aims: To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients. Methods: Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed. Results: During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia. Conclusions: Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.

KW - Anemia

KW - Hemodialysis

KW - N-Acetylcysteine

KW - Oxidative stress

KW - Oxidized low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=77954184657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954184657&partnerID=8YFLogxK

U2 - 10.1159/000317201

DO - 10.1159/000317201

M3 - Article

C2 - 20606481

AN - SCOPUS:77954184657

VL - 116

JO - Nephron - Clinical Practice

JF - Nephron - Clinical Practice

SN - 1660-2110

IS - 3

ER -